Rheumatology International

, Volume 30, Issue 12, pp 1643–1645 | Cite as

Isoniazid-triggered pure red cell aplasia in systemic lupus erythematosus complicated with myasthenia gravis

  • Hideki NakamuraEmail author
  • Akitomo Okada
  • Atsushi Kawakami
  • Satoshi Yamasaki
  • Hiroaki Ida
  • Masakatsu Motomura
  • Daisuke Imanishi
  • Katsumi Eguchi
Case Report


A 47-year-old woman who had been treated for systemic lupus erythematosus (SLE) with myasthenia gravis (MG) was admitted to our hospital with acute onset of severe anemia after administration of isoniazid. Pure red cell aplasia (PRCA) was confirmed by elevated serum iron levels, reticulocytopenia and bone marrow aspiration showing a remarkable reduction of erythroblasts. Finally, cyclosporine A successfully improved PRCA. Although both SLE and MG have the potential complication of PRCA, we report here a case of isoniazid-triggered PRCA.


Pure red cell aplasia Isoniazid Systemic lupus erythematosus Myasthenia gravis Cyclosporine A 



Cyclosporine A


Systemic lupus erythematosus


Myasthenia gravis


Pure red cell aplasia


  1. 1.
    Lim LC (2005) Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure. Hematology. 10:255–259CrossRefPubMedGoogle Scholar
  2. 2.
    Liang TB, Li DL, Yu J, Bai XL, Liang L, Xu SG et al (2007) Pure red cell aplasia due to parvovirus B19 infection after liver transplantation: a case report and review of the literature. World J Gastroenterol 13:2007–2010PubMedGoogle Scholar
  3. 3.
    Atzeni F, Sarzi-Puttini P, Capsoni F, Vulpio L, Carrabba M (2003) Successful treatment of pure red cell aplasia in systemic lupus erythematosus with cyclosporin A. Clin Exp Rheumatol 21:759–762PubMedGoogle Scholar
  4. 4.
    Casadevall N, Cournoyer D, Marsh J, Messner H, Pallister C, Parker-Williams J et al (2004) Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. Eur J Haematol 73:389–396CrossRefPubMedGoogle Scholar
  5. 5.
    Loulergue P, Mir O, Dhote R (2007) Pure red blood cell aplasia and isoniazid use. Emerg Infect Dis 13:1427–1428PubMedGoogle Scholar
  6. 6.
    Lewis CR, Manoharan A (1987) Pure red cell hypoplasia secondary to isoniazid. Postgrad Med J 63:309–310CrossRefPubMedGoogle Scholar
  7. 7.
    Erslev AJ, Soltan A (1996) Pure red cell aplasia: a review. Blood Rev 10:20–28CrossRefPubMedGoogle Scholar
  8. 8.
    Dessypris EN, Redline S, Harris JW, Krantz SB (1985) Diphenylhydantoin-induced pure red cell aplasia. Blood. 65:789–794PubMedGoogle Scholar
  9. 9.
    Mizobuchi S, Yamashiro T, Nonami Y, Yamamoto A, Kume M, Nakaya H et al (1998) Pure red cell aplasia and myasthenia gravis with thymoma: a case report and review of the literature. Jpn J Clin Oncol 28:696–701CrossRefPubMedGoogle Scholar
  10. 10.
    Habib GS, Saliba WR, Froom P (2002) Pure red cell aplasia and lupus. Semin Arthritis Rheum 31:279–283CrossRefPubMedGoogle Scholar
  11. 11.
    Arcasoy MO, Chao NJ (2005) T-cell-mediated pure red-cell aplasia in systemic lupus erythematosus: response to cyclosporin A and mycophenolate mofetil. Am J Hematol 78:161–163CrossRefPubMedGoogle Scholar
  12. 12.
    Sawada K, Hirokawa M, Fujishima N, Teramura M, Bessho M, Dan K et al (2007) Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group. Haematologica. 92:1021–1028CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Hideki Nakamura
    • 1
    Email author
  • Akitomo Okada
    • 1
  • Atsushi Kawakami
    • 1
  • Satoshi Yamasaki
    • 1
  • Hiroaki Ida
    • 1
  • Masakatsu Motomura
    • 2
  • Daisuke Imanishi
    • 3
  • Katsumi Eguchi
    • 1
  1. 1.Unit of Translational Medicine, Department of Immunology and RheumatologyNagasaki University Graduate School of Biomedical SciencesNagasaki cityJapan
  2. 2.Department of Clinical Neuroscience and NeurologyNagasaki University Graduate School of Biomedical SciencesNagasakiJapan
  3. 3.Department of Hematology and Molecular Medicine, Atomic Bomb Disease InstituteNagasaki University Graduate School of Biomedical SciencesNagasakiJapan

Personalised recommendations